Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concurrent FOLFIRINOX plus high intensity focused ultrasound (ALPIUS 900) for locally advanced/borderline resectable pancreatic cancer
KCT0006302Phase 3Not yet recruiting
- Sponsor
- Focused Ultrasound Foundation
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of FOLFIRINOX in pancreatic cancer (PC), sponsored by Focused Ultrasound Foundation. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on KCT0006302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006302.